Why Mirum Pharmaceuticals and Incyte’s zilurgisertib data could reset expectations in FOP treatment
Read how Mirum and Incyte’s zilurgisertib Phase 2 data could reshape FOP treatment, FDA review risk and rare disease strategy.
Pharma & Biotech